Navigation Links
Treatment over a longer period for blood clotting

Venous thromboembolism is a condition which causes clotting in the veins. Typical therapy for venous thromboembolism includes a five- to 10-day course of heparin followed by three to 12 months of the oral drug warfarin. However, the problem with this treatment is that once the patient goes off warfarin, venous thromboembolism recurs. While recurrence rates of this problem are reduced if the patient stays on warfarin, according to previous studies, it// also puts the patient at an increased risk for a major hemorrhage. Researchers have now conducted a study to find out whether keeping patients on a low-dose of warfarin would be beneficial or too much of a risk.

The study included more than 500 patients who received standard treatment and then were assigned to receive a placebo or low-intensity warfarin. Participants were followed to see who had recurrent venous thromboembolism, major hemorrhage, and who died. After four years, researchers found that 37 of the 253 patients assigned to the placebo had recurrent venous thromboembolism, as compared with 14 of the 255 patients on the low-intensity warfarin. This indicated a risk reduction of 64 percent. Furthermore, major hemorrhage occurred in two patients on the placebo and five on the warfarin. Researchers claimed that the reduction in the risk of recurrent venous thromboembolism for patients on low-intensity warfarin, after adjusting for other factors, was between 76 percent and 81 percent.

Andrew Schafer, M.D., from the University of Pennsylvania School of Medicine, in an accompanying editorial said that though researchers claim short-term treatment reduces the risk of recurrent venous thromboembolism by up to 81 percent, doctors are continuing to walk a tightrope for dosing medicine for patients with venous thromboembolism. Although low-intensity warfarin may prevent recurrent venous thromboembolism it is unclear what dosage doctors need to give to prevent recurrence and not cause major bleedin g.


'"/>




Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... Hamden, CT (PRWEB) , ... December 07, 2016 , ... ... has prompted an outpouring of comments on social media that offer a rare glimpse ... adult psychiatrist, leading ADHD authority and New York Times bestselling author, has described people ...
(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... is now promoting to the US market its advanced highly customizable contact technology ... and ODU TURNTAC®. These advanced technologies are ideal for a wide range of ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... consultation services to residents in the Sacramento/Folsom region, is initiating a charity event ... , The Another Choice Another Chance treatment center in Sacramento works to provide ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... One ... regular changing of the securement tape is painful for her. "This is why the ... to patients’ heads," she said. , They then created a prototype of the patent-pending ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... VILLAGE, Calif. , Dec. 6, 2016 ... privately held, clinical-stage medical dermatology and aesthetics ... plc, a privately held specialty pharmaceutical company ... common inflammatory skin conditions, including psoriasis, atopic ... of the agreement, Sienna will make an ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
(Date:12/6/2016)... , Dec. 6, 2016  Regulus Therapeutics Inc. ... leading the discovery and development of innovative medicines ... candidates at its R&D day, held in ... RGLS5040, is an anti-miR targeting microRNA-27 (miR-27) for ... RGLS4326, is an anti-miR targeting microRNA-17 (miR-17) for ...
Breaking Medicine Technology: